In:
Cancer, Wiley, Vol. 120, No. 16 ( 2014-08-15), p. 2448-2456
Abstract:
R1507 is safe and well tolerated but has limited activity in patients with recurrent or refractory bone and soft tissue sarcomas. Additional studies to help identify predictive factors associated with clinical benefit in selected histologies, such as rhabdomyosarcoma, appear to be warranted.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v120.16
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink